Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citranvi Global Multiantigen hCMV Vaccine
- Development stage
- Preclinical
- Lead developer
- Citranvi Biosciences
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Citranvi Biosciences is developing the Citranvi Global Multiantigen hCMV Vaccine, a protein-based biologic candidate for the prevention of human cytomegalovirus (hCMV) infection. The vaccine utilizes a proprietary herpesvirus protein multimeric technology platform licensed from the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), which was originally developed by researchers at the Uniformed Services University of the Health Sciences (USU). This platform enables the production of recombinant proteins in a multimeric format, designed to enhance immunogenicity and stimulate the production of protective antibodies against multiple viral antigens. Currently in preclinical development, the vaccine is intended for women of childbearing age to prevent congenital hCMV transmission and for immunosuppressed individuals, including solid organ and stem cell transplant recipients.
- Other names
- Citranvi hCMV vaccinehCMV vaccine
02
Targets
gB (Human cytomegalovirus glycoprotein B)HCMV Pentamer (HCMV pentameric glycoprotein complex)
Beyond the preview
Go deeper on Citranvi Global Multiantigen hCMV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citranvi Global Multiantigen hCMV Vaccine.